Status:
COMPLETED
Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Psoriasis Vulgaris
Psoriatic Arthritis
Eligibility:
All Genders
Up to 17 years
Brief Summary
This was a multicenter, centrally registered observational study without a control group. This observational study was a specified drug use-results survey conducted under GPSP to collect information o...
Detailed Description
For patients who discontinued or completed this drug before the end of the observation period, the investigator recorded adverse events that occurred within 30 days after the day following the last ad...
Eligibility Criteria
Inclusion
- Patients who have obtained written consent from their legally acceptable representative to cooperate in this survey before the start of treatment with this drug
- Patients aged less than 18 years at the start of treatment with this drug
- Patients newly treated with this drug for any of the following diseases: Psoriasis vulgaris, psoriatic arthritis, pustular psoriasis
Exclusion
- Prior treatment with this drug
- Participation in an interventional study (e.g., a clinical trial) at the time of starting this drug.
Key Trial Info
Start Date :
February 14 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 28 2024
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT05215561
Start Date
February 14 2022
End Date
September 28 2024
Last Update
June 8 2025
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Nagoya, Aichi-ken, Japan, 467-8602
2
Novartis Investigative Site
Fukuoka, Fukuoka, Japan, 814 0180
3
Novartis Investigative Site
Kitakyushu, Fukuoka, Japan, 807-8556
4
Novartis Investigative Site
Obihiro, Hokkaido, Japan, 080 0013